Celgene Earnings Beat Estimates; Raises EPS Guidance
Celgene (CELG) early Thursday beat analysts' Q3 expectations and raised its EPS outlook Thursday, sending its shares up 1.5% in early trading. The biotech said sales rose 14% over the year-ago quarter to $1.42 billion, a hair above analysts' consensus of $1.41 billion. Adjusted earnings rose 26% to $1.29 a share, beating consensus by 2 cents. U.S. sales of its main revenue driver, the cancer drug Revlimid, fell a bit short of expectations at $547
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here